GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education

June 12, 2026 updated by: University of Southern California
This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods. It also assesses patient interest in using an artificial intelligence educational resource.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

AIM 1: Evaluate use of an AI chatbot for HPV vaccine counseling:

PRIMARY OBJECTIVE:

I. To determine patient satisfaction with using an AI chatbot for HPV vaccine counseling.

SECONDARY OBJECTIVE:

I. To understand how patients currently obtain information about cancer care, vaccines, and artificial intelligence.

II. To describe patient experience with the AI-chatbot for vaccine counseling.

AIM 2: Increase rates of HPV vaccine uptake:

PRIMARY OBJECTIVE:

I. To evaluate if implementation of an AI chatbot for HPV vaccine counseling can affect the HPV vaccination rate of new patients served in the gynecologic oncology clinic.

OUTLINE: This is an observational study.

Patients complete a survey on study.

Study Type

Observational

Enrollment (Estimated)

48

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Los Angeles, California, United States, 90033
        • Recruiting
        • USC / Norris Comprehensive Cancer Center
        • Principal Investigator:
          • Xiaoyue M. Guo
        • Contact:
      • Los Angeles, California, United States, 90033
        • Recruiting
        • Los Angeles General Medical Center
        • Principal Investigator:
          • Xiaoyue M. Guo
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients of the LA General gynecologic oncology clinic with a biopsy-proven diagnosis of endometrial cancer.

Description

AI-chatbot Evaluation (Aim 1):

Inclusion Criteria:

  • Patient of the LA General gynecologic oncology clinic
  • Age 18 years or older
  • Previously obtained the HPV vaccination (initial chatbot evaluation)
  • Eligible for HPV vaccination (pilot intervention; age <46)
  • Willing and able to provide informed consent

Exclusion Criteria:

  • Patients who do not speak English or Spanish
  • Patients who do not provide informed consent

HPV vaccination rate (Aim 2):

Inclusion Criteria:

  • Patient of the LA General gynecologic oncology clinic
  • Age 18 years or older
  • Obtained the HPV vaccine

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Observational
Patients complete a survey on study.
Non-interventional study
Other Names:
  • Non-Interventional Observational Study
  • Noninterventional (Observational) Study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Satisfaction Scores
Time Frame: Up to 1 year
Patients will complete a survey to assess their satisfaction with using an AI chatbot for HPV vaccine counseling.
Up to 1 year
HPV Vaccination Rate
Time Frame: Up to 1 year
HPV vaccination rate for patients who received the HPV vaccine counseling with the AI-chatbot
Up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Demographics of patients
Time Frame: Up to 1 year
Will be analyzed using a qualitative description of the demographics of patients involved in this specific study.
Up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Xiaoyue M Guo, University of Southern California

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 12, 2026

Primary Completion (Estimated)

June 9, 2027

Study Completion (Estimated)

June 9, 2028

Study Registration Dates

First Submitted

November 20, 2025

First Submitted That Met QC Criteria

December 10, 2025

First Posted (Actual)

December 12, 2025

Study Record Updates

Last Update Posted (Actual)

June 16, 2026

Last Update Submitted That Met QC Criteria

June 12, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 5U-25-1 (Other Identifier: USC / Norris Comprehensive Cancer Center)
  • P30CA014089 (U.S. NIH Grant/Contract)
  • NCI-2025-03594 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • UP-25-00331 (Other Identifier: USC IRB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endometrial Carcinoma

Clinical Trials on Non-Interventional Study

3
Subscribe